Maxpro Capital (NASDAQ:JMAC) announced in an 8-K this morning that it has entered into a PIPE agreements adding $23.65 million to its combination with drug developer Apollomics.
Of these, $21.35 million was raised at $10 per share as “Series A preferred shares”. These will be convertible into 1.25 common shares each and will be locked up for six months. An additional $2.3 million PIPE was raised at $10 per share without these benefits, but these shares are to come with a 1/4 warrant attached that may be exercised between six months and five years out from close.
The parties originally announced their $932 million deal in September 2022. Foster City, California-based Apollomics is developing a line of drug candidates to treat rare cancers with clinical processes nearing completion in both the US and Chinese treatment markets.
In November, it received an orphan drug designation for its APL-101 drug candidate, which is in Phase II trials to potentially treat non-small cell lung cancer and other cancer types.
Maxpro has a transaction deadline coming up on April 13 and it has already used its two automatic extensions.
Terms Tracker for the Week Ending November 1, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Once again, the past week was all about new issuance while the DeSPAC announcements remain quiet. To kick off November, two SPACs priced IPOs to...
October continued the recent trend of SPAC teams seeking additional extensions beyond their first one, as they work on closing their combinations with the remaining funds after redemptions. Meanwhile, new SPACs are launching IPOs and beginning their search processes, signaling a shift in the market. Extension Votes In October, there were 13 scheduled extension votes....
K&F Growth II (NASDAQ:KFIIU) has filed for a $250 million IPO with aggressive terms and a laser focus on hospitality and gaming targets. The SPAC comes to market with a 24-month initial search clock and a trust that is not overfunded. This makes it only the second of underwriter BTIG’s nine SPACs filed in 2024...
At the SPAC of Dawn During a day of Halloween parties, SPACs adopted a one in, one out policy with two fresh SPACs pricing their IPOs just as two others opted to exit the club via liquidation. Given that the two new SPACs, Bleichroeder I (NASDAQ:BACQU) and Newbury Street II (NASDAQ:NTWOU), will begin trading later...
Bleichroeder Acquisition Corp. I (Nasdaq: BACQU), announced the pricing of its $250 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “BACQU”, Friday, November 1, 2024. The new SPAC intends to focus their efforts on businesses in the technology, media and telecommunications (“TMT”) sector as well as sectors...